Semax

Description

Semax is a synthetic peptide developed in Russia with documented nootropic and neuroprotective capabilities. It primarily influences brain function and has applications in cognitive enhancement and neuroprotection.

Overview

Semax is a synthetically produced peptide originating from Russian research during the 1980s. It is recognized in Russia and Ukraine for treating conditions such as ischemic brain stroke, encephalopathy, optic nerve atrophy, and various cognitive impairments like dementia. The peptide is an analog of the ACTH(4-10) fragment, derived from the adrenocorticotropic hormone (ACTH), though Semax is designed to bypass the hormonal effects of ACTH. Comprising seven amino acid residues, Semax includes the Met-Glu-His-Phe sequence from ACTH (4-7) and a Pro-Gly-Pro fragment. This structural configuration facilitates its passage across the blood-brain barrier, allowing it to reach significant concentrations in brain tissues where it exerts its nootropic and neuroprotective actions. Researchers have also explored modifications such as acetylation and amidation to form N-Acetyl Semax Amidate, which may improve its stability. The research applications of Semax are broad, focusing on improving cognitive function, providing neuroprotection, and regulating mood. Studies demonstrate its ability to enhance memory accuracy in fatigued individuals and increase activity in brain regions associated with emotional processing and episodic memory. Furthermore, Semax has shown promise in managing mood disturbances, particularly in mitigating anxiety-like behaviors under stress. Its neuroprotective properties are well-documented, with clinical trials indicating benefits for stroke patients, including improved motor function and reduced inflammation. It has also shown potential in protecting against nerve damage in glaucoma and mitigating neurotoxic effects from substances like alcohol and certain neurotoxins implicated in Parkinson's disease. Beyond the nervous system, Semax also shows gastroprotective potential, promoting the healing of peptic ulcers by possibly influencing gut microcirculation. However, further investigation into this mechanism is necessary.

Mechanism of Action

Semax functions by stimulating the production of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) within the central nervous system. Additionally, it interacts with the signaling pathways of dopamine, serotonin, and enkephalins. These combined actions contribute to its effects on neurogenesis, neuroprotection, and cognitive processes.

Benefits

• •Enhances cognitive performance
• •Provides neuroprotective effects
• •Supports mood regulation
• •Offers gastroprotective benefits
• •May protect against neurotoxins
• •Increases neurotrophic factors (BDNF, NGF)

Dosing Notes

Semax is typically administered intranasally, with official guidelines from Russia detailing varying dosages based on the condition and formulation (0.1% or 1% solution). For mental fatigue, a dose of 400-900 mcg/day is split across two or three administrations for 3-5 days. Children and adolescents aged 7-18 with mild cognitive dysfunction may receive 200-400 mcg daily, split into two administrations, for 30 days. For optic nerve disorders, 600-900 mcg/day, divided into two or three doses, is given for 7-10 days. Amnestic cognitive impairment linked to cerebrovascular issues may involve a dose range of 200-2000 mcg per application, up to four times daily, for 10-14 days, with a total daily dose of 800-8000 mcg. In cases of moderate ischemic stroke, 2000-3000 mcg are administered three to four times daily, with 3-4 hour intervals, for 10 days, totaling 6000-12000 mcg/day. For severe stroke, doses range from 3000-4000 mcg, given four to six times daily at 2.5–3 hour intervals, for up to 10 days, amounting to 12000-20000 mcg/day. Some research protocols for stroke patients involve cycling 1% intranasal Semax at 6000 mcg/day for 10 days on, followed by 20 days off, and then another 10 days of administration. For injectable research, a suggested daily dose is 500-1000 mcg via subcutaneous injection, for up to 30 days, or 500 mcg/day for up to 60 days, followed by a rest period equivalent to the study duration.

Reported Side Effects

• •Injection site reactions (for injectable forms)

Safety Notes

Semax has not undergone review or approval by the FDA. Research on its full range of effects and long-term safety is limited. Potential risks include injection site reactions if administered via injection.

Scientific References